Mpox Becomes Entrenched in US Population Despite Vaccination Efforts
Mpox continues circulating in the United States with approximately 2,500 cases reported in 2025, suggesting the virus may transition from occasional outbreaks to endemic status. Low vaccination rates with the JYNNEOS vaccine, which is 66-90% effective with two doses, combined with additional unknown factors, contribute to the virus's persistence. Scientists caution that while cases have declined from the 2022 outbreak peak, the virus remains established and shows no signs of disappearing.
The mpox virus that swept globally in 2022 has fundamentally altered its epidemiological pattern in the United States. Rather than disappearing after initial containment efforts, the virus has established a persistent circulation within the domestic population, with case numbers stabilizing at thousands annually despite being substantially lower than peak outbreak figures. The vast majority of current infections stem directly from the original outbreak strain, indicating sustained human-to-human transmission chains within U.S. communities rather than repeated introductions from abroad.
The available preventive tool, the JYNNEOS vaccine, demonstrates strong efficacy when administered as a complete two-dose regimen, yet incomplete vaccination coverage remains a significant barrier to disease control. Beyond vaccination gaps, scientists acknowledge additional unknown mechanisms that may be facilitating the virus's continued transmission at low levels across geographically dispersed populations, representing an area requiring further investigation and epidemiological study.
Mpox's transition to endemic status could reshape public health resource allocation and disease surveillance priorities for years to come. Healthcare systems may face ongoing diagnostic and treatment demands, while vulnerable populations—particularly those in communities experiencing health inequities—could bear disproportionate infection burden. The situation demonstrates how infectious diseases can shift from acute crises to chronic management challenges, potentially affecting healthcare planning, vaccine distribution strategies, and public awareness campaigns if sustained interventions prove necessary.